Our Partnerships

The Company’s strategy of Identify, Prepare, Commercialise is built on partnerships and academic relationships. Established from the Institute of Cancer Therapeutics (ICT) at the University of Bradford, Incanthera retains its active involvement and discussion with the evolution of technologies from the ICT and has an exclusive Pipeline Agreement offering first right to all oncology IP originating from the ICT.

Similarly, Incanthera draws on strengths of its academic and commercial relationships to prepare technologies for commercialisation at the earliest opportunity, minimising risk for shareholders and securing further investment into the Company. Incanthera’s first License Deal was signed in 2017, with current lead product, Skin + CELL, Incanthera’s complementary range of luxury skincare products, the subject of a Business Agreement for global launch through a Direct to Consumer Agency, announced in June 2025.